Serum biomarkers for the evaluation of liver fibrosis: The need for better tests

References (4)

1. Friedman SL, Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 (Suppl 1): S38-53. Castera L, Pinzani M, Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010; 59: 861-6.
2. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assess- ment of liver fibrosis. Hepatology 2011; 53: 325-35. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-9. Parkes J, et al., Performance of serum marker panels for liver fibro- sis in chronic hepatitis C. J Hepatol 2006; 44: 462-74.
3. Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800-12.
4. Yiğit B, Boyle M, ÖZler O, et al. Plasma cell-free DNA methyl- ation: a liquid biomarker of hepatic fibrosis. Gut 2018; pii: gut- jnl-2017-315668. doi: 10.1136/gutjnl-2017-315668. [Epub ahead of print] McPherson, S., et al., Evidence of NAFLD progression from steato- sis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62: 1148- 55. McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol 2017; 112: 740-51.